Antiplatelet So that Blood does not clump

作者：Geiger Joerg^*

来源：Chemie in Unserer Zeit, 2012, 46(6): 366-377.

DOI：10.1002/ciuz.201200568

• Thrombozytenaggregationshemmer
• PDE-Inhibitoren
• COX1-Inhibitoren
• ADP-Rezeptorinhibitoren
• Thrombin-Inhibitoren

Inhibitors of platelet aggregation (%26quot;anti-platelets%26quot;) constitute a remarkably heterogeneous family of drugs, with regard to both chemistry and biochemistry. The rather uncommon diversity and the continuing search for new anti-platelet drugs results from the particular requirements: high efficacy associated with good tolerability especially during long-term treatment, marginal side effects and easy administration. Sophisticated structural modifications to lead compounds are employed to meet these requirements and improve bio-availability and efficacy. While thromboxane synthesis and ADP receptors are currently the most prominent targets of antiplatelet drugs, a number of other promising targets are now evaluated and new drugs are on the verge.

• 出版日期2012-12